Want to see SE:EGTX full AI Analyst Report?
EGTX Stock Chart & Stats
kr6.38
kr0.27(4.42%)
―
--
Day’s Range― - ―
52-Week Rangekr3.63 - kr7.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)792.52K
Market Cap
kr2.79B
Enterprise Valuekr2.11K
Total Cash (Recent Filing)kr142.50M
Total Debt (Recent Filing)kr75.20M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Aug 21, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding464,947,240
10 Day Avg. Volume1,042,665
30 Day Avg. Volume792,519
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr23.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.34
Revenue Forecast (FY)kr396.66M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained TTM revenue growth (+112%) indicates the company is gaining commercial traction or advancing clinical milestones that generate revenue. Over 2–6 months this supports a larger revenue base to scale operations and validates the underlying business model in orphan therapeutics.
Manageable LeverageA debt-to-equity near 0.30 means financial commitments are limited relative to equity, preserving borrowing capacity. This structural balance gives the company time to advance programs without immediate solvency pressure, reducing refinancing urgency in the medium term.
Orphan-disease FocusConcentrating on orphan and rare indications creates structural advantages: regulatory incentives, potential premium pricing, and lower competition. This strategic focus supports durable commercial potential and partner interest, aiding long-term revenue and collaboration opportunities.
Bears Say
Severely Negative Cash FlowVery large negative operating and free cash flow indicate the business is burning cash to fund operations and development. Persistently negative cash flow erodes reserves, forces external financing, and raises dilution risk, constraining long-term strategy and R&D timelines.
Large Net Losses And Weak MarginsExtremely negative net margins and large losses relative to revenue show core operations are not profitable and scalability is unproven. Over months this undermines internal funding, limits reinvestment capacity, and increases dependence on external capital or partnerships.
Capital Erosion And Dilution RiskMaterial equity decline and negative ROE reflect accumulated losses that erode shareholder capital. This structural weakening increases probability of future equity raises, dilutive financings, or unfavorable deal terms, reducing long-term shareholder value.
Egetis Therapeutics AB News
EGTX FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was kr3.63 and its highest was kr7.07 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is kr2.79B.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 16 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Apr 29, 2026. The company reported -kr0.24 earnings per share for the quarter, missing the consensus estimate of -kr0.19 by -kr0.05.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.15.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -kr0.24 in its last earnings report, missing expectations of -kr0.19. Following the earnings report the stock price went up 0.173%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in SE:EGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
EGTX Stock 12 Month Forecast
Average Price Target
kr23.00